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Abstract
The amygdala undergoes aberrant development in autism spectrum disorder (ASD). We previously found that there are
reduced neuron numbers in the adult postmortem amygdala from individuals with ASD compared to typically developing
controls. The current study is a comprehensive stereological examination of four non-neuronal cell populations: microglia,
oligodendrocytes, astrocytes, and endothelial cells, in the same brains studied previously. We provide a detailed
neuroanatomical protocol for defining each cell type that may be applied to other studies of the amygdala in
neurodevelopmental and psychiatric disorders. We then assess whether cell numbers and average volumes differ between
ASD and typically developing brains. We hypothesized that a reduction in neuron numbers in ASD might relate to altered
immune function and/or aberrant microglial activation, as indicated by increased microglial number and cell body volume.
Overall, average non-neuronal cell numbers and volumes did not differ between ASD and typically developing brains.
However, there was evident heterogeneity within the ASD cohort. Two of the eight ASD brains displayed strong microglial
activation. Contrary to our original hypothesis, there was a trend toward a positive correlation between neuronal and
microglial numbers in both ASD and control cases. There were fewer oligodendrocytes in the amygdala of adult individuals
with ASD ages 20 and older compared to typically developing controls. This finding may provide a possible sign of altered
connectivity or impaired neuronal communication that may change across the lifespan in ASD.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder marked by deficits in social cognition and the presence
of restricted and/or repetitive behaviors. It is currently estimated
that 1 out of every 68 newborns in the United States will be
diagnosed with ASD [1]. The amygdala is a medial temporal lobe
structure that modulates social and emotional processing, both of
which are disrupted in ASD. It displays numerous functional
abnormalities in adolescents and adults with the disorder (e.g., [2–
6]). In some children with ASD, the amygdala has an aberrant
growth trajectory marked by early enlargement followed by
normal or even reduced volume by adulthood [7–14].
The amygdala has been associated with the neuropathology of
ASD from the earliest postmortem studies [8,15–16]. We
previously investigated neuron number in the postmortem
amygdala from a cohort of adolescent and adult males with
ASD and found that there are, on average, fewer neurons in ASD
than in typically developing cases [17]. However, the three major
glial populations of the brain, microglia, oligodendrocytes, and
astrocytes, as well as the endothelial cells, all have not been
stereologically examined in either the ASD or typically developing
amygdala.
There is evidence that excessive microglial activation may be
present in ASD. Studies focusing on frontal and visual cortices and
the cerebellum report increased microglial density and aberrant
cell morphology in a subset of ASD brains [18–20]. Microglia are
innate neuroimmune effector cells of the brain, and increase in
number and volume when activated (reviews: [21–22]). Alterations
in cytokine and immune-related gene expression profiles have also
been reported in frontal and temporal cortices in ASD, suggesting
enhanced microglial activation in the disorder [20,23–24].
Moreover, [11C](R)-PK11195, a radiotracer that binds to microg-
lia, is elevated across many regions of the brain in ASD [25].
Given that increased microglial activation has been associated with
lower neuron numbers in temporal lobe structures in several
neurodegenerative conditions [26–28], we hypothesized that our
finding of reduced neuron numbers in the amygdala in ASD might
be related to increased microglial activation in adults with the
disorder.
There is also some evidence for aberrant astrocyte activation in
the frontal cortex and cerebellum of ASD cases [20]. Astrocytes
coordinate innate immune responses and promote environmental
homeostasis in the brain. Glial fibrillary acidic protein (GFAP),
which is upregulated during astrocyte activation, is increased in
multiple brain regions of some ASD cases [20,24,29–30]. As for
oligodendrocytes, there is little evidence of abnormalities in the
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ASD brain. Oligodendrocytes are the most numerous glial
population in the brain and are primarily responsible for
myelinating axons. Interestingly, oligodendrocytes have a high
vulnerability to environmental perturbations such as microglial
activation [31–34]. Lastly, endothelial cell abnormalities in ASD
have not been investigated. Endothelial cells are the primary cell
type that forms the blood vessels innervating the brain. They are
primarily responsible for ensuring proper vascularization and the
integrity of the blood-brain barrier.
In this study, we stereologically examined the microglia,
oligodendrocyte, astrocyte, and endothelial cell populations in
the amygdala overall and in five of its major subdivisions. To
create a foundation for future cellular studies, we provide a
detailed, reliable neuroanatomical protocol for identifying these
cell populations. These are the first stereological estimates to be
published for the major non-neuronal cellular populations of the
typically developing human amygdala. They can also be used as a
baseline for future studies of neurodevelopmental and psychiatric
disorders that involve the amygdala. We then present a
comprehensive stereological study of the non-neuronal cell
populations in the amygdala and its nuclei in ASD relative to
typically developing brains. This study was carried out using the
same cohort of postmortem brains as our previous stereological
study of neuron numbers, with the same nuclear definitions.
Therefore, an additional goal was to determine whether any non-
neuronal alterations, if present, were related to the neuron number
alterations previously reported. Because neuron numbers were
particularly altered in the lateral nucleus, we focused on it as a
region of interest in the study. Finally, due to previous magnetic
resonance imaging findings of age-related changes in pathology in
the amygdala of ASD brains [7-14], we examined whether there
were any differences in these cellular populations between
adolescent and adult brains.
Materials and Methods
Tissue Acquisition and Sectioning
This study utilized postmortem brains from diagnosed ASD
(n = 8) and age-matched typically developing (n = 10) cases
(Table 1) previously examined in stereological analyses of neuron
number [17,35]. Seven of the eight ASD cases were diagnosed via
postmortem administration of the Autism Diagnostic Interview-
Revised [36]. The remaining case had extensive medical records
available indicating that the donor met full DSM-IV criteria for
ASD. All cases were male and had no medical history of other
major neurological or psychiatric disorders. Clinical summaries of
each ASD case are presented in Information S1.
The Institutional Review Board (IRB) Administration of the
University of California, Davis reviewed the study design and
determined that formal IRB approval of the use of human subjects
was not required because the study did not meet US Department
of Health and Human Services criteria for a human subjects study
as it did not involve living individuals and no private identifiable
information was involved. Written informed consent for use of the
tissue in postmortem studies was obtained from the next of kin by
the brain bank or donation center from which the sample was
drawn.
Tissue sectioning for all cases was performed as previously
described [17,35]. Briefly, tissue was removed from the skull and
immersed in formalin for a minimum of 2 months. One 4 cm
block containing the entire rostrocaudal extent of the amygdala
was dissected and placed into cryoprotectant solution (10%
glycerol in 0.1 M phosphate buffer for 2 days and 20% glycerol
for 5 days) in preparation for freezing. The tissue block was frozen
with 2-methyl butane (isopentane) and serially coronally sectioned
into six series of 50-mm-thick sections and two series of 100-mm-
thick sections. Every other section from one 50 mm series (i.e. one
section every 1000 mm) was selected for use in the current
immunohistochemistry study as described below.
Immunohistochemistry
We immunohistochemically stained 50 mm tissue sections for
ionized calcium-binding adaptor molecule 1 (Iba1) and counter-
stained using hematoxylin/eosin (H & E). Additional series from 2
cases (1 ASD case, UMB-4226, and 1 typically developing control
case, UCD H-2-04) were stained for glial fibrillary acidic protein
(GFAP) and counterstained with H & E to assist in developing our
astrocyte nuclei definitions.
Sections were allowed to warm to room temperature, and then
washed 3 times via gentle agitation for 1 minute in double distilled
water (ddH2O) to remove residual cryoprotectant. We then
mounted the sections from 0.1 M acetate (C2H3O2) buffer
(pH = 6.0) onto 30640 microscope glass slides (Brain Research
Laboratories, Newton, MA) and air dried 40 hours prior to
immunohistochemistry to maximize section adhesion. Tissue slides
were then immersed in 3% hydrogen peroxide (H2O2) and
methanol (MeOH) solution for 30 minutes to block general
peroxidase activity and rinsed for 30 seconds in 0.02 M potassium
phosphate buffered saline (KPBS) to remove blocking solution. We
performed antigen retrieval by heating the tissue slides in 0.1 M
citrate (C6H7O7) buffer (pH = 6.0) at 100uC in an uncapped
pressure cooker for 50 minutes, followed by a 60 minute cool
down period under a 10 pounds per square inch (psi) pressure cap.
Tissue slides were washed 3 times via 1 minute immersion in
0.02 M KPBS to remove the citrate buffer.
We then used a wax immunopen to encircle the tissue on the
slide to form a well for immunohistochemistry. All tissue slides
were stored in a humidity chamber from this step through 3,39-
diaminobenzidine tetrachloride (DAB) development. We incubat-
ed tissue slides in a solution of 2% normal goat serum (NGS), 1%
bovine serum albumin (BSA), and 0.5% triton x-100 in KPBS at
room temperature for 3 hours to permeabilize the tissue and block
background staining. Tissue slides were then washed to remove
the solution 3 times via 1 minute immersion in 0.02 M KPBS. We
then incubated the tissue slides with a rabbit polyclonal primary
antibody against Iba1 (1:1000, Wako USA, Richmond, VA) in all
brains. An additional tissue section series from two of the brains
was incubated with a primary antibody against GFAP (1:1000,
Dako, Carpenteria, CA). Primary antibodies were delivered in a
solution containing 0.5% triton x-100 in 0.02 M KPBS. Tissue
slides were incubated in this solution for 40 hours at 4uC then
washed 3 times via 1 minute immersion in 0.02 M KPBS to
remove the primary antibody solution.
We then incubated the tissue slides with 1:200 anti-rabbit
secondary antibody (Vector Laboratories, Burlingame, CA) in
0.5% triton x-100 in 0.02 M KPBS for 2 hours then washed 3
times via 1 minute immersion in 0.02 M KPBS to remove the
solution. The tissue slides were incubated for 1 hour in ABC
reagent (ImmunoBioScience, Everett, WA), prepared according to
the manufacturer’s recommended protocol, with the addition of
0.5% triton x-100, then washed 3 times via 1 minute immersion in
0.02 M KPBS to remove the ABC solution. We then incubated
with 1:200 anti-rabbit secondary antibody (Vector Laboratories,
Burlingame, CA) in 0.5% triton x-100 in 0.02 M KPBS for 1 hour
and washed 3 times via 1 minute immersion in 0.02 M KPBS to
remove the secondary antibody solution. The tissue slides were
then incubated for 30 minutes in ABC reagent (Immuno-
BioScience, Everett, WA), which was prepared according to the
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manufacturer’s recommended protocol, with the addition of 0.5%
triton x-100, and washed 3 times via 1 minute immersion in
50 mM Tris-buffered saline (TBS) in preparation for development.
We developed the tissue slides via 10 minute incubation in 0.05%
DAB (MP Biomedicals, Solon, OH) in 50 mM TBS, then washed
the tissue slides 3 times via 1 minute immersion in 50 mM TBS
and air-dried overnight.
We defatted the tissue and removed the wax immunopen wells
with 2 immersions in 50% chloroform/50% EtOH that were each
2 hours in length. The tissue sections were rehydrated via a
progressive series of 100%/100%/95%/70% EtOH immersions
(4 minutes each). Then, we counterstained via full immersion in
undiluted H & E (Vector Laboratories) for 5 minutes and dipped
briefly in ddH2O to remove excess staining. The tissue slides were
dehydrated via a progressive series of 50%/70%/95%/95%/
100%/100% EtOH immersions (4 minutes each), followed by 3
immersions in 100% xylene washes (4 minutes each). They were
then coverslipped (Brain Research Laboratories) with DPX
mounting medium (Electron Microscopy Services, Hatfield, PA).
Anatomical Definitions of the Amygdala and
Subdivisions
This study utilized previously published delineations (i.e.
contours) for the amygdaloid complex outlined on Nissl stained
sections [17,35] in a series cut in parallel with adjacent Iba1
sections (Figure 1). The delineations defined the whole amygdala
as well as divided it into five subregions: (1) lateral nucleus, (2)
basal nucleus, (3) accessory basal nucleus, (4) central nucleus, and
(5) a region comprising the remaining amygdaloid nuclei not in
subdivisions 1-4, including the anterior cortical nucleus, anterior
amygdaloid area, nucleus of the lateral olfactory tract, periamyg-
daloid cortex, medial nucleus, posterior cortical nucleus, amygda-
lohippocampal area, and intercalated nuclei ("other nuclei"). For
each case, the outlined contours were overlaid onto Iba1
immunohistochemically stained sections using gross morphological
features (e.g., the lateral ventricle) as well as cytoarchitectonic
boundaries and fiber tracts that were visible via the H & E
counterstain (Figure 1).
Stereological Measurements
All assessments were conducted on a Nikon Eclipse 80i
microscope (Nikon Instruments, Melville, NY) with an Optronics
Microfire camera (Optronics, Goleta, CA) using a 1006objective
(1.3 NA) (Nikon Instruments) and Ko¨hler illumination via Stereo
Investigator 9.0 software (MBF Bioscience, Williston, VT). All
stereological quantification was performed with a 1 mm guard
zone and a 3 mm counting zone (depth of counting frame). We
ensured that the primary Iba1 antibody had completely penetrated
the counting zone by examining the bottom 1 mm of the section,
beyond the counting zone, and determining that it consistently
contained robustly stained Iba1-positive cells. Cells were counted if
the topmost point of their H & E counterstained nucleus was in
focus within the 3 mm counting zone. The section thickness was
measured at every counting site and used as a number-weighted
correction factor to correct for variability in tissue shrinkage
(Table 2).
Cells were sampled at a density sufficient to achieve a
Gundersen (m = 1) coefficient of error (CE) ,.10 in all cases for
all cell population estimates in each subdivision of the amygdala
(Table 3). The disector used was 60 mm660 mm in the x-y axis
(3600 mm2) and 3 mm in the z-axis. The disector x-y spacing (grid
size) was set by nucleus: accessory basal nucleus:
715 mm6715 mm, basal nucleus: 950 mm6950 mm, central nucle-
us: 290 mm6290 mm, lateral nucleus: 1040 mm61040 mm, other
nuclei grouping: 950 mm6950 mm. The average numbers of
Table 1. Descriptive information for all cases.
Brain bank number Diagnosis Age Hemisphere PMI Primary/Secondary Cause of Death
UCD H-2-04 Control 11 Left 30 Cardiac Arrest/Renal Failure
BTB-3830 Control 14 Left 19 Asphyxia
BTB-3831 Control 17 Left 24 Motor Vehicle Accident
BTB-3851 Control 18 Left 20 N/A
BTB-3809 Control 24 Left 19 N/A
BTB-4016 Control 25 Left 20 N/A
BTB-3849 Control 27 Left 21 Arteriosclerotic Cardiovascular Disease
BTB-3706 Control 27 Right 21 Asphyxia
BTB-3966 Control 32 Left 17 N/A
UCD H-19-01 Control 44 Left 26 N/A
BTB-3714 ASD 10 Right 24 Drowning
UCD H-4-99 ASD 15 Right 12 Cardiac Arrest/Renal Failure
AN02736 ASD 15 Right 3 Aspiration
AN11206 ASD 16 Right 48 Undetermined
AN00764 ASD 20 Right 24 Motor Vehicle Accident
UMB-4226 ASD 28 Left 18 Monoxide Poisoning
AN16961 ASD 36 Left 24 Cardiac Arrest/Renal Failure
AN06746 ASD 44 Left 31 Acute Myocardial Infarction
Capsule clinical summaries for ASD cases are provided in Information S1.
ASD, Autism Spectrum Disorder. N/A, not available.
doi:10.1371/journal.pone.0110356.t001
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sampled cells and coefficients of error by nucleus are presented in
Table 3.
All glial cell number estimations were conducted via the optical
fractionator feature of Stereo Investigator. All glial nucleus and cell
body volume estimations were conducted via the isotropic
nucleator feature of Stereo Investigator. The H & E stained
nucleus volume was estimated for every cell recorded. The Iba1-
positive cell body volume was estimated for every microglial cell
recorded.
A single rater (JM) collected all data in this study. A reliability
assessment was performed in 4 cases for all cell populations,
demonstrating.95% intra-rater reliability for each population as
determined by intra-class correlation.
Statistical Analysis
All analyses were conducted using IBM SPSS Statistics 21.0
(IBM Corp., Armonk, NY). Although our sample size was too
small to perform a Shapiro-Wilk test for normality, the glial
number and volume data did not appear to have a normal
distribution. Therefore, we examined the population differences
between the ASD and typically developing control cases via non-
parametric Mann-Whitney U test. Relationships between cell
populations were assessed via non-parametric correlation. To
further investigate the presence of developmental effects, we
separated the cases into adolescent (age,20) and adult (age 20+)
subgroups.
Image Preparation
The full microglial arbor was not fully in focus in any single
plane of view for image capture. Therefore, we assembled a 3D
image montage to visualize all microglial processes in Figure 2. To
do this, we acquired serial images from a single section at 1 mm
depth intervals. The microglial arbor was reconstructed from the
processes that were in focus in each serial image using Adobe
Photoshop 11.0.2 (Adobe Systems Incorporated, San Jose, CA
USA). This resulted in a flattened, two-dimensional composite of
the microglial cell’s full arbor within the section. We edited several
incidental processes that were not part of the microglial arbor out
of the image to make the labels easier to read. Contrast, brightness,
and color levels were adjusted to make the image panels more
visually consistent in Figures 2, 3, and 6.
Results
Glial Cell Definitions
Four cell populations, microglia, oligodendrocytes, astrocytes,
and endothelial cells, were identified in the series of tissue sections
stained for Iba1 immunoreactivity and counterstained with H & E.
The Iba1 immunoreactivity stained the cell bodies of microglial
cells specifically, while the H & E stain marked the nuclei of all cell
types. We identified microglial cells based on the presence of Iba1-
positive staining. The remaining cell types, oligodendrocytes,
astrocytes, and endothelial cells, were identified based on their H
& E stained nuclear morphology and size, as described below and
summarized in Table 4. Several previous studies using Nissl-
stained material were used as a reference to develop our protocols
for the current study [37–39]. Morphological criteria for
identifying neurons were previously published [17,35]. The other
cell types are as follows:
i. Microglia
The microglial cells are readily distinguished from other cellular
populations based on the presence of Iba1 staining. On H & E
stained sections, microglial nuclei range from 2 mm to 6 mm in
diameter, which is typically larger than oligodendrocytes and
smaller than astrocytes (Figure 2, Table 4). The microglial nuclei
are moderately heterochromatic, containing approximately 3–6
large, dark granules of chromatin and a moderate density of
smaller, lighter granules of chromatin. The H & E staining
intensity of the microglial nuclei is also intermediate to that of
oligodendrocytes and astrocytes. Microglial nuclear shape is highly
variable, with spherical, elliptical, irregularly shaped, and trian-
gular nuclei. Due to the variability in microglial nuclear
characteristics, and the fact that they are often intermediate to
those of oligodendrocytes and astrocytes, we used Iba1 staining
exclusively in our final stereological quantification to identify
microglia.
However, in addition to marking resident microglia, Iba1 also
marks monocytes that have infiltrated into the brain across the
blood-brain barrier [40], at which point they are commonly
referred to as macrophages. In the current study, we excluded
perivascular (blood vessel-associated) macrophages from our
stereological quantification. Perivascular macrophages can be
distinguished from microglia via two criteria. First, the perivascu-
lar macrophages have a rod-shaped morphology that is aligned
Figure 1. Delineations of the amygdala subregions examined. A. Delineation outlined on a Nissl stained section and B. transferred onto an
Iba1- and H & E- stained section and aligned using morphological features, fiber tracts, and cytoarchitectonic boundaries. AB: accessory basal nucleus,
B: basal nucleus, C: central nucleus, L: lateral nucleus, O: "other nuclei", a subregion comprising the remaining amygdaloid nuclei, including the
anterior cortical nucleus, anterior amygdaloid area, nucleus of the lateral olfactory tract, periamygdaloid cortex, medial nucleus, posterior cortical
nucleus, amygdalohippocampal area, and intercalated nuclei. Scale bar: 2 mm.
doi:10.1371/journal.pone.0110356.g001
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with a blood vessel. (The blood vessels are visible because they
contain numerous H & E-stained endothelial cell nuclei that are
linearly aligned with each other). Second, the perivascular
macrophages extend all of their processes close and parallel to
the neighboring blood vessel. Normal microglia extend their
processes evenly in all directions from the cell body.
We qualitatively examined the microglia in each case for signs
of activation (Figure 3) (reviews: [21–22]). Resting microglia have
small and spherical cell bodies, and the processes are thin and well
defined (Figure 3A). Slightly activated microglia have marginally
thickened but relatively straight processes, with a few small swollen
spots visible (Figure 3B). Moderately activated microglia have
noticeably enlarged cell bodies, with thick, unevenly swollen,
tortuous processes (Figure 3C–D). Strongly activated microglia
have further enlarged cell bodies and a loss of processes (Fig 3E).
The remaining processes are short and thick, as the cell
approaches an amoeboid morphology. Finally, extremely activated
microglia have an even larger cell bodies and few if any processes,
appearing to largely assume an amoeboid morphology (Figure 3F).
ii. Astrocytes
We distinguished astrocytes from the other glial populations
based on their nuclear morphology in the H & E counterstain
(Table 4). The astrocyte nuclei are typically 6–10 mm in diameter,
with a minimum diameter of 5 mm. They have a high density of
small, light granules of chromatin, but no more than 4 large
distinct, dark clusters of chromatin. They are lightly stained overall
by H & E compared to other glial cell nuclei and elliptical or
spheroid in shape (Figure 2). We confirmed the reliability of our
definitions by examining H & E stained nucleus morphology in an
adjacent series of tissue sections stained with GFAP immunore-
activity (Figure 2).
iii. Oligodendrocytes
Oligodendrocyte nuclei are distinguished from astrocytes and
microglia based on their nuclear morphology in the H & E
counterstain. Our definition of oligodendrocyte nuclei is consistent
with previously published definitions in Nissl-stained tissue [38–
39,41] (Table 4). The oligodendrocyte nuclei are typically
2.5 mm–5 mm in diameter, with a maximum diameter of 6 mm.
They have a high density of large, dark granules of chromatin
(typically 5–15), with a low density of smaller, lighter granules
compared to other glial nuclei (Figure 2). They stain more darkly
via H & E than any other nucleus type, and have a dark, distinct
nuclear boundary and are primarily spherical or oval in shape.
iv. Endothelial cells
Endothelial cell nuclei are distinguishable from all other glial
nuclei primarily by their morphology, which is typically either rod-
shaped or folded over, with angular borders (Figure 2B).
Occasionally, they may appear ovoid in large blood vessels.
Because of their association with blood vessels, each endothelial
cell nucleus also typically appears in linear alignment with several
others (Figure 2B). The endothelial cell nuclei are typically as large
as astrocyte nuclei in at least one axis (.5 mm), and sometimes
much larger (up to 25 mm). They contain only small, light granules
of chromatin at a low to moderate density, with no large, dark
granules visible. They are the most lightly stained of all nucleus
Figure 2. Morphologies of examined cellular populations.
Tissue stained brown with A. Iba1-positive primary antibody to identify
microglial cells and B. GFAP-positive primary antibody to identify
astrocytes. Counterstained purple with H & E. Scale bar: 10 mm.
doi:10.1371/journal.pone.0110356.g002
Figure 3. Microglial morphology from resting to very strongly
activated in an ASD case that displayed strong microglial
activation (AN02736). A. Resting microglial morphology (volume
,75 mm3). B. Slightly activated microglial morphology (volume
,150 mm3). C. Activated microglial morphology (volume ,275 mm3).
D. Activated microglial morphology (volume ,400 mm3). E. Strongly
activated microglial morphology (volume ,525 mm3) F. Very strongly
activated microglial morphology (volume ,900 mm3). Scale bar: 10 mm.
doi:10.1371/journal.pone.0110356.g003
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types examined. Their nuclear boundaries are distinct and dark
relative to their staining intensity.
Cell Numbers
Average population numbers for each cell type examined in the
whole amygdala and lateral nucleus are displayed in Figure 4.
Individual case data for each cell type in the amygdala as a whole
is reported in Table 2. Raw average population numbers, nuclear
volumes, and somal volumes (when available) for each cell type
examined in each amygdala subdivision are reported in Table 5.
i. Microglia
There were 7.56106 microglia on average in the typically
developing control cases, compared with 8.46106 microglia on
average in the ASD cases (not significant, ns) (Figure 4, Table 5).
In the lateral nucleus specifically, there were 2.266106 microglia
on average in typically developing control cases, compared with
2.616106 microglia in ASD cases (ns) (Table 5).
Microglial somal volumes were highly heterogeneous in all cases
examined. Both the typically developing control and ASD cases
had an average microglial cell body volume of 275 mm3 (ns)
(Table 5).
Two ASD cases, AN00764 (20 y.o.) and AN02736 (15 y.o.), had
average microglial somal volumes that were above the high end of
the typically developing control range (by 19.9% and 10.1%,
respectively) (Figure 5, Table 2). Examining these cases qualita-
tively, many of the microglial cells had a strongly activated
morphology (Figure 6). These two cases also had the highest
microglial numbers of any cases examined, which were ,4.2%
and ,10.1% above the high end of the control range (Figure 5,
Table 2). A third ASD case, AN06746, had a microglial number
that was 1.6% above the high end of the control range (Figure 5A,
Table 2), but an average microglial volume in the middle of the
control range. AN02736 and AN00764 were also outliers for both
microglial volume and number in the lateral nucleus specifically
(Figure 5C–D).
ii. Oligodendrocytes
There were 28.66106 oligodendrocytes on average in the
amygdala of typically developing control cases, and 27.56106 in
ASD cases (ns) (Figure 4, Table 5). Examining lateral nucleus
specifically, there were 10.56106 oligodendrocytes on average in
control cases, compared with 10.76106 oligodendrocytes on
average in ASD cases (ns) (Table 5). The average oligodendrocyte
nucleus volume was 117 mm3 in control cases, and 115 mm3 in
ASD cases (p = .90) (Table 5).
iii. Astrocytes
There were 9.006106 astrocytes on average in the amygdala of
control cases, and 9.736106 astrocytes on average in ASD cases
(ns) (Figure 4, Table 5). Examining lateral nucleus specifically,
there were 2.916106 astrocytes on average in control cases, and
3.316106 astrocytes on average in ASD cases (ns) (Table 5). The
average astrocyte nucleus volume was 238 mm3 in control cases
and 247 mm3 in ASD cases (ns) (Table 5).
iv. Endothelial Cells
There were 4.996106 endothelial cells on average in the
amygdala of typically developing control cases, and 5.606106
endothelial cells on average in the amygdala of ASD cases (ns)
(Figure 4, Table 5). Examining the lateral nucleus specifically,
there were 1.696106 endothelial cells on average in control cases
and 1.976106 endothelial cells on average in ASD cases (ns)
(Table 5). The average endothelial cell nucleus volume was
259 mm3 in control cases and 261 mm3 in ASD cases (ns) (Table 5).
v. Potential Confounds and Covariates
We examined postmortem pre-fixation interval (PMI) as a
possible confound for the cell number and somal volume findings.
PMI did not differ significantly between the ASD and typically
developing control groups, nor was it significantly correlated with
any outcome measure. We did not fully examine hemisphere
effects because there was only one control case that had tissue
drawn from the right hemisphere. However, within the ASD
group, the source hemisphere did not covary significantly with any
outcome measure. There was insufficient information on two cases
Table 4. Criteria used to classify glia by nuclear morphology.
Criterion Oligodendrocytes Microglia Astrocytes Endothelial Cells
Size Small, ,6 mm diameter Variable, 2–6 mm diameter Large,.5 mm diameter Large, longest axis.5 mm
Shape Commonly spherical, with
some oval shapes observed.
Highly variable, including
spherical, oval, irregularly
shaped, and triangular
nuclei.
Spherical or oval. Oval shapes are
more common than in
oligodendrocytes.
Typically folded over,
elongated ovals. Rarely very
large and oval in large blood
vessels.
Staining Intensity High Intermediate Low Low
Granularity High with larger granules
predominating (usu. 5–15
visible) over smaller ones.
Moderate density of small,
light granules with a few
larger granules interspersed
(usu. 3–6).
High density of smaller, light
granules incorporating fewer large
granules (usu. 0–4).
Typically exhibit only a
moderate density of light
granules.
Nucleus Boundary
Morphology
Rounded Rounded or angular (less
commonly.)
Rounded Angular or rounded (less
commonly.)
Staining Intensity of
Nucleus Boundary
Moderate to dark Moderate to light Light Moderate to dark
Staining of Cytoplasm
Around Nucleus
No cytoplasm stained around
nucleus.
No cytoplasm stained
around nucleus in H&E.
Cell body fully visualized
via Iba1.
A thin rim of cytoplasm may be
stained immediately adjacent to
the nucleus.
No cytoplasm stained around
nucleus.
doi:10.1371/journal.pone.0110356.t004
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regarding possible seizure history (AN02736 and CAL101; see
Information S1). However, none of the ASD cases had a diagnosis
of epilepsy, nor was it the primary cause of death. We were not
able to examine quantitative relationships with clinical character-
istics or outcomes, genetic profile, immunological features, brain
mass, or postmortem tissue pH due to insufficient data. We did not
find any clear qualitative relationships with clinical characteristics
or outcomes (Information S1).
Correlations
There were positive trend correlations between neuron number
and microglial number in both typically developing control cases
(r(10) = .61; p = .06) and ASD cases (r(8) = .67; p = .07) (Figure 7A).
There was also a positive trend correlation between microglial
number and neuron number in the lateral nucleus of typically
developing cases only (r(10) = 0.60, p = .07) (Figure 7B). In the
ASD cases, the correlations between neuron number and
microglial number were significantly positive in the accessory
basal nucleus (r(8) = 0.86, p = .01), basal nucleus (r(8) = 0.91, p,
0.01), and the other nuclei grouping (r(8) = 0.91, p,0.01).
Age-related Analyses
There were fewer oligodendrocytes in adult ASD cases older
than 20 years than adult typically developing control cases
(p = .04) (Figure 8). This effect was significant in the basal nucleus
(p = .04) specifically, with a trend in the lateral nucleus (p = .07).
There was a trend towards fewer oligodendrocytes in the adult
ASD subgroup compared to the adolescent ASD subgroup ages
10–19 (p = .06) (Figure 8). No age-related effects were observed in
microglia, astrocytes, or endothelial cells.
Discussion
In this study, we examined the microglial, oligodendrocyte,
astrocyte, and endothelial cell populations in the amygdala of
postmortem brains from adolescent and adult male individuals
that either had ASD or were typically developing controls. There
were three primary objectives in this study: 1) to provide detailed
anatomical definitions and stereological measurements for each
cell population, 2) to determine if there were differences between
typically developing control brains and the ASD diagnostic group
in cell size and number, 3) to examine if non-neuronal cell
measures were correlated with previously reported neuron number
estimates, and 4) to investigate age-related differences in these
populations in either typically developing control or ASD brains.
This study is, to our knowledge, the first comprehensive
stereological examination of the major glial populations to use a
neuroanatomical protocol that distinguishes the microglial popu-
lation via Iba1 staining [37–39]. Because microglial nucleus
morphologies overlap with those of the astrocyte and to some
extent oligodendrocyte populations [38], this approach substan-
tially improves confidence in the identification of all three major
glial types. The protocol is a reliable method for segregating the
major glial cell populations that may be applied to future
stereological studies of many other brain regions and cohorts.
This is also the first study to stereologically examine the numbers
of individual glial populations in the typically developing
Figure 4. Summary of cell numbers in whole amygdala of ASD
and typically developing control brains. A. Adolescents ,20 years
of age, no significant differences between ASD and controls in any cell
population. B. Adults.20 years of age, significantly fewer oligodendro-
cytes in ASD than typically developing brains (p = .04), trend towards
fewer neurons in ASD adults compared to controls (p = .10). C.
Adolescents and adults combined, significantly fewer neurons in ASD
than control cases (p = .03). Error bars reflect standard deviation. Neuron
number data originally published in [17,35].
doi:10.1371/journal.pone.0110356.g004
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amygdala, rather than reporting densities, which may be
susceptible to variable tissue shrinkage [38]. We found that there
are on average 7.5 million microglia, 28.6 million oligodendro-
cytes, 9.0 million astrocytes, and 5.0 million endothelial cells in the
amygdala of typically developing adult, male control subjects 11–
44 years of age. This is compared to 12.2 million neurons in our
prior paper [35]. These estimates may serve as a baseline for
future studies of glia in neurodevelopmental and psychiatric
disorders, such as schizophrenia and major depressive disorder,
where neuron number and oligodendrocyte density abnormalities
have been reported in the amygdala [38,42–44]. Similarly,
comparative studies of amygdala glia numbers in animal models
(e.g., [41,45–47]) or typical human development may use these
numbers as a point of comparison.
For our study of adolescent and adult ASD brains, there are no
group differences with typically developing control brains in any of
the cell populations we examined. There are, however, three
primary findings in this study: 1) two ASD brains display evidence
of aberrant microglial morphology and number, 2) microglia
number demonstrates a trend positive correlation with neuron
number in both ASD and control cases, and 3) oligodendrocyte
numbers are reduced in adults with ASD relative to typically
developing adults. The microglial activation and oligodendrocyte
number findings should be considered preliminary due to the small
subgroup sizes involved. Below we discuss our findings in each of
the cell populations examined. The findings emphasize the need
for future comprehensive studies of the amygdala in ASD over the
course of development in larger cohorts.
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Figure 5. Microglial number and size stereological measures in
ASD and typically developing amygdala. Whole amygdala: A.
microglial number and B. average microglial somal volume. Two ASD
cases with the highest microglial numbers also have the highest
microglial volumes. Lateral nucleus: C. microglial number and D.
average microglial somal volume. Numbers next to case markers
indicate subject age.
doi:10.1371/journal.pone.0110356.g005
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Microglia
Two out of the eight ASD brains examined, AN00764 (20 y.o.)
and AN02736 (15 y.o.), exhibit strong microglial activation with
both larger and more numerous microglia than the maximum
typically developing control values. This activation is also unlikely
to be an artifact of postmortem changes specific to these cases.
First, there is no correlation between postmortem interval and
either microglial number or average volume in either ASD or
typically developing control brains. Second, there are no signs of
excessive activation in any typically developing control brains even
though many of them had a postmortem pre-fixation interval
longer than 24 hours. Third, the ASD brain with the longest
postmortem interval, near 48 hours (AN11206), demonstrates no
alteration in either microglial number or somal size. By contrast, a
brain with a postmortem interval of only 3 hours (AN02736)
demonstrates substantial microglial activation.
Although preliminary, our findings, in combination with
previous studies of microglia in the disorder, suggest that excessive
microglial activation may be present in a subset of patients.
Approximately four out of thirteen cases appeared to be similarly
strongly affected in a prior study of frontal cortex [18]. This
finding is also consistent with observations of global heterogeneity
in immune abnormalities in ASD (reviews: [48–50]). However, a
recent study of the frontoinsular and visual cortices in ASD found
a much higher frequency of aberrant microglial activation, with
the large majority of cases consistently affected [19]. What might
account for this discrepancy? It is possible that activation may be
more likely to be present in some brain regions than others in
Figure 6. Low magnification fields of view comparing Iba1-positive microglial morphologies. A. Typically developing amygdala (BTB-
3831, 17 y.o.) with minimal microglial activation. B. ASD amygdala (AN11206, 16 y.o.) with minimal microglial activation. C. ASD amygdala with strong
microglial activation (AN02736, 15 y.o.). Scale bar: 50 mm.
doi:10.1371/journal.pone.0110356.g006
Figure 7. Relationship between microglial number and neuron
number in ASD and typically developing cases. A. Trend positive
correlation in microglial and neuron number in both typically
developing control (p = .06) and ASD (p= .07) whole amygdala and B.
in typically developing (p = .07) but not ASD lateral nucleus. Numbers
next to case marker indicate subject age.
doi:10.1371/journal.pone.0110356.g007
Figure 8. Oligodendrocyte number in the whole amygdala of
ASD and typically developing control cases, grouped by age.
Oligodendrocyte number is significantly lower in the adult ASD group
ages 20+ compared to typically developing controls ages 20+ (p = .04).
There is a trend towards lower oligodendrocyte numbers in the adult
ASD group compared to the adolescent ASD group ages 10–19 (p = .06).
Numbers next to case markers indicate subject age.
doi:10.1371/journal.pone.0110356.g008
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ASD. However, since microglial activation appears to be present
in only a subset of ASD cases, the difference may also reflect the
particular collections of cases examined in these papers. Therefore,
at present we cannot be certain what underlies the discrepancy.
Additional studies of microglial features in an expanded number of
ASD brains are needed to determine precisely how frequently
microglial activation is present in the disorder, and whether it is
consistently present across many regions of the brain.
This question is further complicated by the fact that the two
ASD cases that show strong signs of excessive microglial activation
in this study may each have a different profile of activation. One of
the ASD cases (AN02736, 15 y.o.) that appeared to have strong
activation had the highest microglial number but second highest
average volume, while the other (AN00764, 20 y.o.) had fewer
microglia but a higher average somal volume. A third ASD case
(AN07646, 44 y.o.) had a microglial number just above the high
end of the typically developing control range, but an average
microglial somal volume in the middle of the range. Increases in
microglial number typically occur over long periods of chronic
activation, while profound changes in microglial morphology can
happen within a few days (reviews: [15,46]). Therefore, these cases
might reflect different profiles of activation. AN02736, with a
higher microglial number but lower average microglial somal
volume, might have more chronic but less intense activation.
AN00764, with higher average microglial somal volume and lower
microglial number, might have more severe but recent activation.
Alternately, the degree of microglial activation could vary over
time in ASD. If this were true, the cases might have been in slightly
different phases of activation when they passed away. Unfortu-
nately, due to the small number of activated cases examined in this
study, it’s unclear which of these scenarios is correct. Additional
studies of microglial features in a large number of ASD brains are
needed to determine whether there is heterogeneity in microglial
activation profiles in the disorder. Gene expression, cytokine, and
PET studies of microglial activation in ASD [20,23–25] can also
help to elucidate whether there are distinct profiles of microglial
activation.
Microglia/Neuron Relationships
What roles might excessive microglial activation be playing in
the ASD patients where it is present? We initially predicted that
excessive microglial activation in the ASD amygdala might be
related to our previous finding of lower neuron numbers in the
same cohort of cases [17]. This was based on multiple studies of
several neurodegenerative disorders describing both excessive
microglial activation and neuron loss [26–28]. In addition,
microglia and neurons are more closely spatially associated in
ASD frontal cortex than in typical brains [8]. Therefore, we
expected that the activated microglia might be performing
phagocytic functions on damaged or dying neurons. In fact,
contrary to our hypothesis, increased microglial number is not
negatively correlated with neuron number, but instead has a trend
positive correlation in both ASD and typically developing brains.
If microglial activation is not associated with lower neuron
number in ASD, what might the close spatial relationship of these
two populations in the disorder reflect? Activated microglia may
naturally move closer to neurons, while not significantly affecting
their survival or activity. In this case, microglial activation might
reflect activation of the broader immune system in some ASD
patients. This could be due to any of several causes: increased
sensitivity to pro-inflammatory factors, a pro-inflammatory
infection of the brain, a disruption of the blood-brain barrier, or
a reaction downstream from the development of autoimmunity to
one or more brain proteins (e.g., [51–55]). Alternately, activated
microglia might be playing a protective role. Microglia can protect
neurons with synaptic abnormalities [56] by regulating their
function via release of trophic factors and cytokines [57–58] or
stripping excess synapses [59–61].
Oligodendrocytes
We found that there are a lower number of oligodendrocytes in
the amygdala of adults with ASD relative to age-matched typically
developing controls. There is also a trend towards lower numbers
in adult ASD relative to adolescent ASD cases. These findings
must be considered preliminary due to the small subgroup sizes,
particularly given that there are no differences in oligodendrocyte
number when the age groups are combined. Nevertheless, it will
be important to determine in future studies whether there may be
a decline in oligodendrocyte numbers in older individuals with
ASD. A loss of oligodendrocytes could significantly impact the
functional connectivity of the amygdala and present significant
cognitive difficulties for older patients with ASD [62–63]. If
present, this alteration could be due to environmental perturba-
tions, such as elevation of pro-activation cytokines like TNF-a, to
which oligodendrocytes are highly vulnerable ([32], although this
finding requires further investigation [64]). Additional studies
examining the oligodendrocyte population across the lifespan in
ASD are needed in order to determine whether there are
abnormalities in this population in older patients with the disorder.
Astrocytes and Endothelial Cells
The absence of significant alterations in the astrocyte and
endothelial cell populations in ASD is also noteworthy. The
absence of group differences in the astrocyte population does not
necessarily indicate that there is no astrocyte activation in ASD, as
astrocytes do not proliferate significantly when they are activated.
Prior studies have found both qualitative morphology changes that
suggest activation and an increase in the levels of GFAP, a protein
whose expression increases during astrocyte activation, in ASD
[20,30]. The absence of a difference in endothelial cell numbers,
meanwhile, suggests that there is no grossly abnormal vascular-
ization in the amygdala in ASD.
Summary
In this comprehensive study of non-neuronal cells in the
amygdala of adolescents and adults with ASD, we found no global
differences in cell numbers and sizes. However, we found
alterations in both the microglia and oligodendrocyte populations
in subsets of ASD patients that require further investigation. It is
now critical to describe the full developmental trajectory of glial
and neuronal abnormalities in ASD across multiple brain regions.
In particular, which cellular abnormalities are present in pediatric
cases, at an age when the behavioral characteristics of the disorder
first manifest? However, our findings make it clear that it is
important to study cohorts of older people with ASD as well.
Alterations such as a reduction in oligodendrocyte numbers later
in life might reflect subtle but increasing cognitive difficulties that
have not yet been described. Given consistent evidence of
heterogeneity in microglial activation, future studies must increase
the number of brains available in order to dissect out possible
phenotypic subgroups in the ASD population and investigate
behavioral, immunological, and genetic correlations. This knowl-
edge will provide substantial insight into the underlying neurobi-
ology of ASD, pointing the way towards effective phenotype
identification leading to targeted pharmacological intervention.
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